Cargando…

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro‐arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay (CiPA) was proposed that integrates multi‐ion channel pharmacology data in vitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhihua, Ridder, Bradley J., Han, Xiaomei, Wu, Wendy W., Sheng, Jiansong, Tran, Phu N., Wu, Min, Randolph, Aaron, Johnstone, Ross H., Mirams, Gary R., Kuryshev, Yuri, Kramer, James, Wu, Caiyun, Crumb, William J., Strauss, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492074/ https://www.ncbi.nlm.nih.gov/pubmed/30151907 http://dx.doi.org/10.1002/cpt.1184

Ejemplares similares

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
por: Li, Zhihua, et al.
Publicado: (2019)

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
por: Delaunois, Annie, et al.
Publicado: (2021)

Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies
por: Delaunois, Annie, et al.
Publicado: (2021)

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
por: Delaunois, Annie, et al.
Publicado: (2023)

Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)
por: Yoon, Seung-Hyun, et al.
Publicado: (2023)

CiPA-compliant assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine
por: Amuzescu, Bogdan, et al.
Publicado: (2021)

Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019)

Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study
por: Vicente, Jose, et al.
Publicado: (2017)

Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
por: Thomet, Urs, et al.
Publicado: (2021)

In silico assessment on TdP risks of drug combinations under CiPA paradigm
por: Qauli, Ali Ikhsanul, et al.
Publicado: (2023)

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment
por: Chang, Kelly C., et al.
Publicado: (2017)

Five years of the CiPA project (2013–2018): what did we learn?
por: Yim, Dong-Seok
Publicado: (2018)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
por: Dutta, Sara, et al.
Publicado: (2017)

Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs
por: Han, Sungpil, et al.
Publicado: (2019)

Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study
por: Vicente, Jose, et al.
Publicado: (2019)

Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study
por: Millard, Daniel, et al.
Publicado: (2018)

Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach
por: Li, Zhihua, et al.
Publicado: (2019)

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)
por: Strauss, David G., et al.
Publicado: (2021)

Proarrhythmia Induced by Propafenone: What is the Mechanism?
por: Femenia, Francisco, et al.
Publicado: (2010)

Transgenic Rabbit Models in Proarrhythmia Research
por: Baczkó, István, et al.
Publicado: (2020)

Proarrhythmia and Oncotherapy: So Much To Be Done!
por: Kovacs, Richard J.
Publicado: (2021)

Cost-effectiveness of the hospital nutrition screening tool CIPA
por: Suárez-Llanos, José Pablo, et al.
Publicado: (2019)

HoPaCI-DB: host-Pseudomonas and Coxiella interaction database
por: Bleves, Sophie, et al.
Publicado: (2014)

Automated Algorithm for J-T(peak) and T(peak)-T(end) Assessment of Drug-Induced Proarrhythmia Risk
por: Johannesen, Lars, et al.
Publicado: (2016)

Uncertainty assessment of proarrhythmia predictions derived from multi-level in silico models
por: Kopańska, Karolina, et al.
Publicado: (2023)

Congenital Insensitivity to Pain with Anhidrosis (CIPA): A Case Report
por: Safari, A, et al.
Publicado: (2011)

A Case Report of Congenital Insensitivity to Pain and Anhidrosis (CIPA)
por: KARIMI, Mehran, et al.
Publicado: (2012)

Proarrhythmia in a Patient With Heart Failure on Therapy With Amiodarone
por: Semerdzhieva, Niya E, et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
por: Polak, Sebastian, et al.
Publicado: (2015)

Corrigendum to “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm” [Toxicology and Applied Pharmacology volume 394C (2020) 114961]
por: Ridder, Bradley J., et al.
Publicado: (2020)

A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm
por: Ridder, Bradley J., et al.
Publicado: (2020)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2023)

Congenital Insensitivity to Pain and Anhydrosis (CIPA) Syndrome; A Report of 4 Cases
por: Daneshjou, Khadije, et al.
Publicado: (2012)

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias
por: Koike, Hideki, et al.
Publicado: (2016)

Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia
por: Ezeani, Martin, et al.
Publicado: (2017)

The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk
por: Thind, Munveer, et al.
Publicado: (2020)

Right ventricular lead proarrhythmia: A novel intervention for an under-recognized phenomenon
por: Hayase, Justin, et al.
Publicado: (2017)

Effect of hydroxychloroquine on proarrhythmia risk assessment using human iPSC-derived cardiomyocytes
por: Yanagida, Shota, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tnqq2r034hc0v9fpnstfjsdprf